Unique gene-silencing and structural properties of 2'-fluoro-modified siRNAs.
作者信息
Manoharan Muthiah, Akinc Akin, Pandey Rajendra K, Qin June, Hadwiger Philipp, John Matthias, Mills Kathy, Charisse Klaus, Maier Martin A, Nechev Lubomir, Greene Emily M, Pallan Pradeep S, Rozners Eriks, Rajeev Kallanthottathil G, Egli Martin
机构信息
Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA.
出版信息
Angew Chem Int Ed Engl. 2011 Mar 1;50(10):2284-8. doi: 10.1002/anie.201006519. Epub 2011 Jan 31.
Abstract
摘要
相似文献
1
Unique gene-silencing and structural properties of 2'-fluoro-modified siRNAs.
Angew Chem Int Ed Engl. 2011 Mar 1;50(10):2284-8. doi: 10.1002/anie.201006519. Epub 2011 Jan 31.
2
Modified siRNAs for the study of the PAZ domain.
Chem Commun (Camb). 2010 Jun 28;46(24):4270-2. doi: 10.1039/c003221b. Epub 2010 May 19.
3
Contributions of 3'-overhang to the dissociation of small interfering RNAs from the PAZ domain: molecular dynamics simulation study.
J Mol Graph Model. 2007 Mar;25(6):784-93. doi: 10.1016/j.jmgm.2006.07.002. Epub 2006 Jul 11.
4
5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo.
Nucleic Acids Res. 2017 Jul 27;45(13):7581-7592. doi: 10.1093/nar/gkx507.
5
New opportunities for designing effective small interfering RNAs.
Sci Rep. 2019 Nov 6;9(1):16146. doi: 10.1038/s41598-019-52303-5.
6
Unexpected origins of the enhanced pairing affinity of 2'-fluoro-modified RNA.
Nucleic Acids Res. 2011 Apr;39(8):3482-95. doi: 10.1093/nar/gkq1270. Epub 2010 Dec 22.
7
Crystal structure, stability and in vitro RNAi activity of oligoribonucleotides containing the ribo-difluorotoluyl nucleotide: insights into substrate requirements by the human RISC Ago2 enzyme.
Nucleic Acids Res. 2007;35(19):6424-38. doi: 10.1093/nar/gkm664. Epub 2007 Sep 18.
8
Structural insights into RISC assembly facilitated by dsRNA-binding domains of human RNA helicase A (DHX9).
Nucleic Acids Res. 2013 Mar 1;41(5):3457-70. doi: 10.1093/nar/gkt042. Epub 2013 Jan 29.
9
Chemical modification of siRNA.
Curr Opin Mol Ther. 2010 Apr;12(2):158-67.
10
Expanding the Scope of 2'-SCF3 Modified RNA.
Chemistry. 2015 Jul 13;21(29):10400-7. doi: 10.1002/chem.201500415. Epub 2015 Jun 12.
引用本文的文献
1
The Effect of 2'F-RNA on I-Motif Structure and Stability.
Molecules. 2025 Aug 30;30(17):3561. doi: 10.3390/molecules30173561.
2
Chemical Modifications in Nucleic Acid Therapeutics.
Methods Mol Biol. 2025;2965:57-126. doi: 10.1007/978-1-0716-4742-4_3.
3
The XNA alphabet.
Nucleic Acids Res. 2025 Jul 8;53(13). doi: 10.1093/nar/gkaf635.
4
Systematic analysis of siRNA and mRNA features impacting fully chemically modified siRNA efficacy.
Nucleic Acids Res. 2025 Jun 20;53(12). doi: 10.1093/nar/gkaf479.
5
A first-in-class EGFR-directed KRAS G12V selective inhibitor.
Cancer Cell. 2025 Jun 16. doi: 10.1016/j.ccell.2025.05.016.
6
Improving the potency prediction for chemically modified siRNAs through insights from molecular modeling of individual sequence positions.
Mol Ther Nucleic Acids. 2024 Dec 5;36(1):102415. doi: 10.1016/j.omtn.2024.102415. eCollection 2025 Mar 11.
7
Technologies for Targeted RNA Degradation and Induced RNA Decay.
Chem Rev. 2024 Dec 11;124(23):13301-13330. doi: 10.1021/acs.chemrev.4c00472. Epub 2024 Nov 5.
8
Atom-Modified gDNA Enhances Cleavage Activity of TtAgo Enabling Ultra-Sensitive Nucleic Acid Testing.
Adv Sci (Weinh). 2024 Jul;11(28):e2403120. doi: 10.1002/advs.202403120. Epub 2024 May 10.
9
Cholesterol-Modified Anti-Il6 siRNA Reduces the Severity of Acute Lung Injury in Mice.
Cells. 2024 Apr 30;13(9):767. doi: 10.3390/cells13090767.
10
RNAi-based drug design: considerations and future directions.
Nat Rev Drug Discov. 2024 May;23(5):341-364. doi: 10.1038/s41573-024-00912-9. Epub 2024 Apr 3.
本文引用的文献
1
Recent advances in small interfering RNA sensing by the immune system.
N Biotechnol. 2010 Jul 31;27(3):236-42. doi: 10.1016/j.nbt.2010.02.015. Epub 2010 Feb 26.
2
Chemical modification of siRNA.
Curr Protoc Nucleic Acid Chem. 2009 Dec;Chapter 16:Unit 16.3. doi: 10.1002/0471142700.nc1603s39.
3
The RNA-induced silencing complex: a versatile gene-silencing machine.
J Biol Chem. 2009 Jul 3;284(27):17897-901. doi: 10.1074/jbc.R900012200. Epub 2009 Apr 1.
4
Development of lipidoid-siRNA formulations for systemic delivery to the liver.
Mol Ther. 2009 May;17(5):872-9. doi: 10.1038/mt.2009.36. Epub 2009 Mar 3.
5
Molecular imaging study on in vivo distribution and pharmacokinetics of modified small interfering RNAs (siRNAs).
Oligonucleotides. 2008 Sep;18(3):201-12. doi: 10.1089/oli.2008.0133.
6
The many roles for fluorine in medicinal chemistry.
J Med Chem. 2008 Aug 14;51(15):4359-69. doi: 10.1021/jm800219f. Epub 2008 Jun 21.
7
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics.
Nat Biotechnol. 2008 May;26(5):561-9. doi: 10.1038/nbt1402. Epub 2008 Apr 27.
8
Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway.
Nature. 2007 Oct 11;449(7163):745-7. doi: 10.1038/nature06179. Epub 2007 Sep 26.
9
RNA interference tolerates 2'-fluoro modifications at the Argonaute2 cleavage site.
Chem Biodivers. 2007 May;4(5):858-73. doi: 10.1002/cbdv.200790073.
10
RNAi therapeutics: a potential new class of pharmaceutical drugs.
Nat Chem Biol. 2006 Dec;2(12):711-9. doi: 10.1038/nchembio839.
Zotero 插件